The short interest in biotech stocks is mixed, judging by the short interest changes between the September 14 and September 28 settlement dates. There were notable swings in shares sold short from…
With a couple of exceptions, the short interest in biotech stocks is on the rise again, judging by the short interest changes from September 14 settlement date versus the August 31 settlement…
Key research changes have been made in the last few days over at Bank of America/Merrill Lynch’s research coverage. The firm published its 2013 target for an S&P 500 Index target of…
The short interest in biotech stocks is generally falling, judging by the short interest changes from August 31 settlement date versus the August 15 settlement date. We have tracked the key short…
Apple Inc. (NASDAQ: AAPL) pushes for a ban on eight Samsung phones. (Reuters) Best Buy Co. Inc. (NYSE: BBY) will allow former chairman Richard Schulze to review its books with an eye…
The short interest in biotech stocks is generally rising, judging by the short interest changes from August 15 settlement date versus the July 31 settlement date. We have tracked the key short…
The short interest data is out from the July 31 settlement date and, with a couple of notable exceptions, short sellers generally have retreated from their gambles on biotech firms. For the…
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen from Wall St. research calls this Tuesday morning. Amgen Inc. (NASDAQ: AMGN) raised to Buy at Lazard. American Tower…
Gilead Sciences Inc. (NASDAQ: GILD) is seeing shares surge today on news that Bristol-Myers Squibb Co. (NYSE: BMY) has run into some unforseen safety issues with a hep-C candidate called INX-189. Gilead’s…
The three major US stock indexes opened higher this morning following European Central Bank president Mario Draghi’s promise to “do whatever it takes to preserve the euro” (our coverage here). What he…
GileadGilead Sciences, Inc. (NASDAQ: GILD) has a product chest that includes Atripla, Truvada, Viread, Complera/Eviplera, and Emtriva for the treatment of HIV infection in adults. While Gilead has been diversifying its products…
GlobeImmune, Inc. is the latest biotech to file for an initial public offering. Financial terms were not disclosed but the first filing is for up to $69 million in common stock. This…
Biotech is a sector which is often mixed with a hodge-podge of winners and losers based on news flow from analysts and/or key drug developments which often have very little to do with…
News from Abbott Laboratories (NYSE: ABT) on its positive Phase II study results from two different interferon-free hepatitis C treatment has the entire drug sector up in arms as it pertains to…
Jon OggEach weekend we review the many analyst calls we track during the week. Some turn out to be very insightful and some turn out to be not so great. For better…
